SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-006098
Filing Date
2022-04-27
Accepted
2022-04-27 16:16:35
Documents
61
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20220331x10q.htm   iXBRL 10-Q 978560
2 EX-31.1 ettx-20220331xex31d1.htm EX-31.1 13544
3 EX-31.2 ettx-20220331xex31d2.htm EX-31.2 12835
4 EX-32.1 ettx-20220331xex32d1.htm EX-32.1 8748
  Complete submission text file 0001558370-22-006098.txt   5073811

Data Files

Seq Description Document Type Size
5 EX-101.SCH ettx-20220331.xsd EX-101.SCH 46906
6 EX-101.CAL ettx-20220331_cal.xml EX-101.CAL 37426
7 EX-101.DEF ettx-20220331_def.xml EX-101.DEF 198480
8 EX-101.LAB ettx-20220331_lab.xml EX-101.LAB 384347
9 EX-101.PRE ettx-20220331_pre.xml EX-101.PRE 313718
55 EXTRACTED XBRL INSTANCE DOCUMENT ettx-20220331x10q_htm.xml XML 771571
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 22859783
SIC: 2834 Pharmaceutical Preparations